DR-TB Regimen Will Save 190,000+ Additional Lives and $1.29B by 2035
The six-month, all-oral BPaL/M regimens for the treatment of drug-resistant TB (DR-TB) are already changing the trajectory of DR-TB care
The six-month, all-oral BPaL/M regimens for the treatment of drug-resistant TB (DR-TB) are already changing the trajectory of DR-TB care
The investment case for global health R&D is increasingly evidence-based. Impact Global Health’s new Ripple Effect analysis tracks what happens
A new analysis, published in IJTLD Open, from South Africa and the Philippines further confirms that six-month, all-oral BPaL/M regimens
NEW YORK (September 12, 2025)—Lupin Limited, a leading pharmaceutical company headquartered in India, has been granted prequalification by the World
In the global fight to end tuberculosis (TB), the Desmond Tutu TB Centre (DTTC) at Stellenbosch University in South Africa
New York, NY (August 29, 2025) – TB Alliance announced the appointment of Dr. Soraya Madani as Senior Vice President,
As Senior Vice President of Program and Alliance Management, Dr. Schostack played a vital role in advancing TB drug development
Capacity building program in the Philippines empowers Bangladesh NTP managers to scale up BPaL and BPaL/M regimens MAKATI CITY, PHILIPPINES—PeerLINC
A new economic evaluation has added powerful evidence to the already strong case for wide, global adoption of BPaL and
The World Health Organization’s (WHO) new guidance on Country Preparedness for the Introduction and Appropriate Use of Antibiotics highlighted TB